ArticleAnnals of internal medicine2023
Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.
Article in Annals of internal medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Cost-Effectiveness and Budget Impact of Lung Cancer Screening: A Systematic Review.PharmacoEconomics · 2026Pooled it
- The Role of Price Variation in Economic Analyses for Cancer Screenings: A Rapid Review.Applied health economics and health policy · 2026Pooled it
- Effectiveness and implementation challenges of mobile low-dose computed tomography units for early lung cancer detection: a systematic review.Frontiers in public health · 2026Pooled it
- Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.Public health reviews · 2026Pooled it
- Pooled it
- Acceptability and perceptions of personalised risk-based cancer screening among health-care professionals and the general public: a systematic review and meta-analysis.The Lancet. Public health · 2025Pooled it
- Pooled it
- A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials.Nature communications · 2025Trial
- Integrating Deep Learning of Low-Dose CT Imaging With Clinical Data for Lung Cancer Risk Prediction.Chest · 2026Article
- Cost-Effectiveness of Smoking Cessation Interventions Integrated Into Lung Cancer Screening.JAMA network open · 2026Article
- Benefits and harms of lung cancer screening strategies in Argentina: a modeling study.Lancet regional health. Americas · 2026Article
- Clinical usefulness of polygenic risk scores in risk prediction models for lung cancer screening and lung nodule management.Translational oncology · 2026Article
- Performance of smoking duration-based lung cancer screening eligibility criteria: a comparative modeling study.Journal of the National Cancer Institute · 2026Article
- Machine learning outperforms serum creatinine for early risk stratification of hepatorenal syndrome: a prospective single-center validation.Hepatology international · 2026Article
- Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.International journal of cancer · 2026Article
- Improving ovarian cancer risk assessment using a machine learning model developed on data from the Prostate Lung Colorectal Ovarian Cancer Screening Trial.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026Article
- Regulatory role of IL-17-mediated inflammatory pathways in lung cancer initiation and progression.Discover oncology · 2026Review
- Healthcare professionals' perspectives on a population-based lung cancer screening programme in Flanders: a cross-sectional survey study.BMC health services research · 2026Article
- Eligibility and Prognostic Performance of Smoking Duration-Based Versus Pack-Year-Based U.S. National Lung Cancer Screening Criteria Across Racial and Ethnic Groups.Annals of internal medicine · 2026Article
- Who is more likely to receive up-to-date lung cancer screening? Identifying key barriers using principal component analysis and SHAP modeling: a weighted cross-sectional analysis of the 2024 BRFSS.Frontiers in public health · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
Abstract
backgroundIn their 2021 lung cancer screening recommendation update, the U.S. Preventive Services Task Force (USPSTF) evaluated strategies that select people based on their personal lung cancer risk (risk model-based strategies), highlighting the need for further research on the benefits and harms of risk model-based screening.
objectiveTo evaluate and compare the cost-effectiveness of risk model-based lung cancer screening strategies versus the USPSTF recommendation and to explore optimal risk thresholds.
designComparative modeling analysis. DATA SOURCES: National Lung Screening Trial; Surveillance, Epidemiology, and End Results program; U.S. Smoking History Generator. TARGET POPULATION: 1960 U.S. birth cohort. TIME HORIZON: 45 years. PERSPECTIVE: U.S. health care sector.
interventionAnnual low-dose computed tomography in risk model-based strategies that start screening at age 50 or 55 years, stop screening at age 80 years, with 6-year risk thresholds between 0.5% and 2.2% using the PLCOm2012 model. OUTCOME MEASURES: Incremental cost-effectiveness ratio (ICER) and cost-effectiveness efficiency frontier connecting strategies with the highest health benefit at a given cost. RESULTS OF BASE-CASE ANALYSIS: Risk model-based screening strategies were more cost-effective than the USPSTF recommendation and exclusively comprised the cost-effectiveness efficiency frontier. Among the strategies on the efficiency frontier, those with a 6-year risk threshold of 1.2% or greater were cost-effective with an ICER less than $100 000 per quality-adjusted life-year (QALY). Specifically, the strategy with a 1.2% risk threshold had an ICER of $94 659 (model range, $72 639 to $156 774), yielding more QALYs for less cost than the USPSTF recommendation, while having a similar level of screening coverage (person ever-screened 21.7% vs. USPSTF's 22.6%). RESULTS OF SENSITIVITY ANALYSES: Risk model-based strategies were robustly more cost-effective than the 2021 USPSTF recommendation under varying modeling assumptions. LIMITATION: Risk models were restricted to age, sex, and smoking-related risk predictors.
conclusionRisk model-based screening is more cost-effective than the USPSTF recommendation, thus warranting further consideration. PRIMARY FUNDING SOURCE: National Cancer Institute (NCI).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.